Advanced search
Publication Cover
Cancer Biology & Therapy Volume 23, 2022 - Issue 1
Submit an article Journal homepage
3,030
Views
1
CrossRef citations to date
0
Altmetric
Review

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome

Kristi Y. LeeMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAORCID Iconhttps://orcid.org/0000-0002-6228-4972View further author information
ORCID Icon,
Cindy H. ChauMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
,
Douglas K. PriceMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
&
William D. FiggMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2428-5613View further author information
ORCID Icon
Pages 136-138 | Received 29 Nov 2021, Accepted 13 Dec 2021, Published online: 06 Feb 2022

References

  • Cravatt BF, Wright AT, Kozarich JW. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu Rev Biochem. 2008;77:383–414. doi:10.1146/annurev.biochem.75.101304.124125.
  • Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, et al. Metabolic changes are associated with melphalan resistance in multiple myeloma. J Proteome Res. 2021;20(6):3134–3149. doi:10.1021/acs.jproteome.1c00022.
  • Choi K-M, Cho E, Bang G, Lee S-J, Kim B, Kim J-H, Park S-G, Han EH, Chung Y-H, Kim JY, et al. Activity-based protein profiling reveals potential dasatinib targets in gastric cancer. Int J Mol Sci. 2020;21(23):E9276. doi:10.3390/ijms21239276.
  • Liu -D-D, Zou C, Zhang J, Gao P, Zhu Y, Meng Y, Ma N, Lv M, Xu C, Lin Q, et al. Target profiling of an anticancer drug curcumin by an in situ chemical proteomics approach. Methods Mol Biol Clifton NJ. 2021;2213:147–161. doi:10.1007/978-1-0716-0954-5_13.
  • Deng H, Lei Q, Wu Y, He Y, Li W. Activity-based protein profiling: recent advances in medicinal chemistry. Eur J Med Chem. 2020;191:112151. doi:10.1016/j.ejmech.2020.112151.
  • Wang S, Tian Y, Wang M, Wang M, Sun G-B, Sun X-B. Advanced activity-based protein profiling application strategies for drug development. Front Pharmacol. 2018;9:353. doi:10.3389/fphar.2018.00353.
  • Lovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E, Williams ED, Engelsberger E, Xu C, Bakker AT, et al. A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer. J Am Chem Soc. 2021;143(23):8911–8924. doi:10.1021/jacs.1c03950.
  • Michaelidou K, Kladi-Skandali A, Scorilas A. Kallikreins as biomarkers in human malignancies. In: Preedy VR, Patel VB, editors. Biomarkers in cancer. Springer (Netherlands): Dordrecht; 2014. p. 1–25. doi:10.1007/978-94-007-7744-6_18-1.
  • Heal WP, Dang THT, Tate EW. Activity-based probes: discovering new biology and new drug targets. Chem Soc Rev. 2011;40(1):246–257. doi:10.1039/c0cs00004c.
  • Willems LI, Overkleeft HS, van Kasteren SI. Current developments in activity-based protein profiling. Bioconjug Chem. 2014;25(7):1181–1191. doi:10.1021/bc500208y.
  • Weerapana E, Wang C, Simon GM, Richter F, Khare S, Dillon MBD, Bachovchin DA, Mowen K, Baker D, Cravatt BF. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature. 2010;468(7325):790–795. doi:10.1038/nature09472.
  • Dong Y, Loessner D, Irving-Rodgers H, Obermair A, Nicklin JL, Clements JA. Metastasis of ovarian cancer is mediated by Kallikrein related peptidases. Clin Exp Metastasis. 2014;31(1):135–147. doi:10.1007/s10585-013-9615-4.
  • Gong W, Liu Y, Seidl C, Dreyer T, Drecoll E, Kotzsch M, Bronger H, Dorn J, Magdolen V. Characterization of Kallikrein-related peptidase 4 (KLK4) MRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients. PloS One. 2019;14(2):e0212968. doi:10.1371/journal.pone.0212968.
  • Ward CC, Kleinman JI, Brittain SM, Lee PS, Chung CYS, Kim K, Petri Y, Thomas JR, Tallarico JA, McKenna JM, et al. Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications. ACS Chem Biol. 2019;14(11):2430–2440. doi:10.1021/acschembio.8b01083.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.